|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Astra_Zeneca_Group
gptkb:Bruton_tyrosine_kinase_inhibitor
gptkb:Genzyme_Genetics
|
|
gptkbp:activities
|
gptkb:Bruton_tyrosine_kinase_inhibitor
|
|
gptkbp:appointed_by
|
oral capsule
|
|
gptkbp:approves
|
gptkb:2017
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Calquence
|
|
gptkbp:category
|
Category D
not recommended
|
|
gptkbp:clinical_trial
|
Phase 3
monotherapy or in combination with other agents
ongoing studies for various cancers
|
|
gptkbp:contraindication
|
active infections
severe hepatic impairment
|
|
gptkbp:discovered_by
|
gptkb:temple
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:formulation
|
capsule form
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Acalabrutinib
|
|
gptkbp:ingredients
|
C24 H26 Cl N5 O2 S
|
|
gptkbp:interacts_with
|
CY P3 A inducers
CY P3 A inhibitors
|
|
gptkbp:is_atype_of
|
L01 X X40
|
|
gptkbp:is_available_in
|
multiple countries
|
|
gptkbp:is_used_for
|
treatment of chronic lymphocytic leukemia
treatment of mantle cell lymphoma
|
|
gptkbp:lifespan
|
approximately 2.5 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:temple
|
|
gptkbp:metabolism
|
primarily metabolized by CY P3 A4
|
|
gptkbp:monitors
|
0 A0 D1 F1 D5 B
|
|
gptkbp:pharmacokinetics
|
inhibits B-cell receptor signaling
oral bioavailability is approximately 25%
|
|
gptkbp:population
|
adults with specific types of blood cancers
|
|
gptkbp:products
|
gptkb:Zanubrutinib
gptkb:Tafasitamab
gptkb:Ibrutinib
|
|
gptkbp:research_focus
|
hematological malignancies
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
bruising
diarrhea
|
|
gptkbp:storage
|
store at room temperature
|
|
gptkbp:targets
|
B cells
|
|
gptkbp:type_of
|
1420477-60-6
|